Miyoshi Toru, Ito Hiroshi, Horinaka Shigeo, Shirai Kohji, Higaki Jitsuo, Orimo Hajime
Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Department of Cardiology and Nephrology, Dokkyo Medical University, Mibu, Japan.
Pulse (Basel). 2017 Jan;4(Suppl 1):11-16. doi: 10.1159/000448464. Epub 2016 Dec 23.
The cardio-ankle vascular index (CAVI) was developed in Japan and is a blood pressure-independent index of arterial stiffness from the origin of the aorta to the ankle. In recent years, it has been studied by many researchers worldwide, and it is strongly anticipated that it will play a role as a predictive factor for arteriosclerotic diseases. The objective of this study was to examine the benefits of using CAVI as a predictor of cardiovascular events in high-risk patients.
This prospective multicenter study to evaluate the usefulness of the CAVI to predict cardiovascular events in Japan (CAVI-J) is a cohort study with central registration. Participants (n = 3,000) will be scheduled to enroll and data will be collected for up to 5 years from entry of participants into the study. To be eligible to participate in the CAVI-J study, individuals have to be aged between 40 and 74 years and have at least one of the following risk factors for arteriosclerosis: (1) type 2 diabetes mellitus; (2) high-risk hypertension; (3) metabolic syndrome; (4) chronic kidney disease (stage 3), or (5) history of coronary artery disease or noncardiogenic cerebral infarction. The primary endpoints of this study are cardiovascular death, nonfatal myocardial infarction, and stroke. The secondary endpoints are composite cardiovascular events including all cause death, angina pectoris with revascularization, new incidence of peripheral artery disease, abdominal aortic aneurysm, aortic dissection, heart failure requiring hospitalization, and deterioration in renal function. The cutoff for CAVI against the incidence of cardiovascular events will be determined.
心踝血管指数(CAVI)由日本研发,是一种从主动脉起点到脚踝的与血压无关的动脉僵硬度指标。近年来,全球众多研究人员对其进行了研究,人们强烈预期它将作为动脉硬化疾病的预测因素发挥作用。本研究的目的是检验在高危患者中使用CAVI作为心血管事件预测指标的益处。
这项旨在评估CAVI预测日本心血管事件实用性的前瞻性多中心研究(CAVI-J)是一项采用中央登记的队列研究。参与者(n = 3000)将按计划入组,从参与者进入研究开始收集长达5年的数据。要符合参与CAVI-J研究的条件,个体年龄必须在40至74岁之间,且至少具有以下动脉硬化危险因素之一:(1)2型糖尿病;(2)高危高血压;(3)代谢综合征;(4)慢性肾脏病(3期),或(5)冠状动脉疾病或非心源性脑梗死病史。本研究的主要终点是心血管死亡、非致死性心肌梗死和中风。次要终点是复合心血管事件,包括全因死亡、需要血运重建的心绞痛、外周动脉疾病新发病例、腹主动脉瘤、主动脉夹层、需要住院治疗的心力衰竭以及肾功能恶化。将确定CAVI预测心血管事件发生率的临界值。